ESPE Abstracts (2023) 97 P1-514

ESPE2023 Poster Category 1 Growth and Syndromes (75 abstracts)

Addition of genetic workup in children with isolated short stature to improve the diagnostic yield for growth hormone treatment

Idoia Martinez de Lapiscina 1,2,3,4,5,6 , Matthias Zürcher 1 , Christoph Saner 1,2 & Christa E. Flück 1,2

1Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 2Department for BioMedical Research, University of Bern, Bern, Switzerland. 3Research into the genetics and control of diabetes and other endocrine disorders, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain. 4CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. 5CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. 6Endo-ERN, Amsterdam, Netherlands

Introduction: Short stature is a common finding that affects per definition about 3% of the population. Isolated, severe short stature may be treated successfully with recombinant human growth hormone (rhGH). Currently, rhGH is offered to short children with specific disorders or biochemically proven growth hormone deficiency (GHD). However, biochemical testing for GHD is artificial and therefore controversial. Adding genetic testing may improve the diagnostic workup. In this pilot study, we performed whole exome sequencing (WES) in children with isolated short stature with biochemically proven GHD or severe idiopathic short stature (ISS) with a normal growth hormone stimulation test to evaluate the added value of a molecular diagnosis.

Methods: Individuals were divided into groups: A) patients with isolated GHD and GH test peak <7ng/dl (13/30, 43.3%); B) isolated GHD and GH test peak 7-10ng/dl (10/30, 33.3%), and C) ISS with GH test peak >10 ng/dl (7/30, 23.3%). WES was performed and analysed with a specific, in-house data filtering algorithm tailored for growth disorders. We used several in silico tools to predict the impact of gene variants and searched for disease-causing variants in literature and in HGMD and ClinVar. Variants were classified according ACMG guidelines.

Results: So far, we studied 30 children with isolated GHD or ISS that are part of a larger study from the University Children’s Hospital Bern. We identified 17 disease causing or candidate gene variants in 13 of 30 patients (43.3%). These were from group A (6/13, 46.1%), followed by group B (5/10, 50.0%) and group C (2/7, 28.6%). Three variants were found in genes that are involved in the GH/IGF axis (GH2, POU1F1, STAT5B), four in components of cartilage extracellular matrix (ACAN, HSPG2, PRG4), five in components of fundamental cellular processes (ARID1B, OCRL, PTCH1, SH3BP2, TP63), four in genes involved in intracellular pathways (PTPN11, RAF1) and one variant in other genes related to syndromic SS (RUNX2).

Conclusions: We identified disease-causing or candidate variants in almost half of the children with isolated, severe short stature in a broad range of genes. These were found in children with isolated GHD and ISS, thus correlation with biochemical testing seems poor. No genotype-phenotype correlation was observed. The high diagnostic yield of WES in the workup of short children demonstrates the added value of a molecular diagnosis. Genetic testing, together with auxiological and biochemical methods may improve the current clinical routine care of patients with short stature and rhGH.

Volume 97

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sep 2023 - 23 Sep 2023

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.